Korean Team Starts AI Tear-Drop Eye Disease Platform
A Catholic University of Korea team and Inha University engineers began a five-year project to develop an AI-assisted platform for diagnosing ocular surface disease from a tiny tear sample.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Professor Na Kyung-sun, head of ophthalmology at Yeouido St. Mary's Hospital, was selected for the National Research Foundation of Korea's 2026 Future Challenge Research Support Program. Her team will receive a total of KRW 800 million over five years to develop the diagnostic platform.
The Catholic University of Korea is leading the project with Professor Kim Dae-yu's electrical and computer engineering team at Inha University. The collaboration will combine ophthalmic clinical experience, sensor technology and AI to pursue a new diagnostic approach for ocular surface disease.
What the team is developing
The planned platform is intended to analyze a tear sample about the size of a single drop. The research team will integrate that small-sample approach with sensors and AI for ocular surface disease assessment.
The project formally brings together ophthalmology and engineering: the Catholic University of Korea contributes clinical expertise, while Professor Kim's Inha University team participates from electrical and computer engineering. The announced funding period is five years.
Current scope and limits
This development marks the start of a funded research project, not the introduction of a test into routine care. K-Health and the Korean medical outlet's reports did not address clinical validation results, availability, accuracy, cost or a launch schedule.
People considering any future eye test should consult a qualified ophthalmologist about its purpose and evidence. Individual variation, possible side effects of sample collection or related procedures, and recovery considerations should be discussed according to the actual method eventually used.
Questions for a consultation
Ask which ocular surface conditions a future version of the platform is designed to assess and how the tear sample would be collected. A clinician can also explain how an AI-assisted result would fit with an eye examination and other diagnostic information.
Patients can ask what evidence supports clinical use, whether individual variation affects interpretation, and what side effects or recovery issues apply to the sampling method. These questions distinguish the announced research aim from a test already available in practice.
Frequently asked questions
Can one tear drop diagnose eye disease?
The research team has started developing an AI-assisted platform that aims to assess ocular surface disease using about one drop of tears. This is a research objective; the reports from K-Health and a Korean medical outlet did not present clinical validation results or announce routine availability.
Who is developing the AI tear test?
The Catholic University of Korea is leading the project with Professor Kim Dae-yu's electrical and computer engineering team at Inha University. Professor Na Kyung-sun of Yeouido St. Mary's Hospital was selected for the National Research Foundation of Korea program supporting the work.
How long will the AI tear test project run?
The research team is scheduled to receive KRW 800 million in total over five years. The funding supports development of the ocular surface disease diagnostic platform.
Questions to ask an ophthalmologist
- Which ocular surface conditions is this platform intended to assess?
- How would the tear sample be collected and analyzed?
- What clinical evidence would be needed before using the test in care?
- How could individual variation affect interpretation of an AI-assisted result?
- What side effects and recovery considerations could apply to the sampling method?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
